{"source_content":"本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。请务必阅读末页声明。医药生物行业推荐（维持）Q3业绩增速环比有所回升风险评级：中风险医药生物行业2020年三季报业绩综述2020年11月16日魏红梅SAC执业证书编号：S0340513040002电话：0769-22119410邮箱：whm2@dgzq.com.cn医药生物（申万）指数走势资料来源：东莞证券研究所，Wind相关报告投资要点：◼医药生物行业整体业绩:2020Q3业绩增速有所回升。2020年前三季度，SW医药生物行业（剔除B股，共353家样本公司）实现营业总收入13519.43亿元，同比增长2.44%；实现归属于母公司股东的净利润1315.2亿元，同比增长24.84%；实现扣非归母净利润1141.7亿元，同比增长28.59%。2020Q3，SW医药生物行业分别实现营收和归母净利润为5558.78亿元和573.85亿元，分别同比增长9.4%和39.15%，Q3业绩增速较Q1和Q2有所回升。细分板块中，前三季度业绩表现最好的是医疗器械，主要是受益疫情。化学原料药、生物制品、医药商业和医疗服务业绩均实现正增长，化学制剂和中药业绩仍有所下滑。从单季业绩来看，Q3化学原料药业绩增速环比有所回落，医疗器械保持快增，化学制剂、中药、生物制品、医药商业和医疗服务业绩增速环比均有所回升。◼子行业业绩情况如下：◼1）化学原料药：2020Q3增速有所回落。2020年前三季度，SW化学原料药板块实现营业总收入771.85亿元，同比增长5.16%，增速同比下降3个百分点；实现归属于母公司股东的净利润125.7亿元，同比增长14.76%，增速同比下降7.7个百分点。2020Q3，SW化学原料药板块营收和归母净利润分别同比增长2.71%和-15.67%，Q3收入增速环比回落主要受产品价格环比回落影响所致，净利润同比有所下滑主要受投资收益减少影响所致。◼2）化学制剂：2020Q3业绩增速环比有所回升。2020年前三季度，SW化学制剂板块实现营业总收入2242.98亿元，同比下降8.46%；实现归属于母公司股东的净利润213.87亿元，同比下降0.15%；实现扣非归母净利润171.35亿元，同比下降6.04%。2020Q3，板块营收和归母净利润分别同比增长-2.03%和36.1%，业绩增速较Q1和Q2有所回升。◼3）中药：Q3业绩增速有所回升。2020年前三季度，SW中药板块实现营业总收入2242.98亿元，同比下降8.46%；实现归属于母公司股东的净利润213.87亿元，同比下降0.15%；实现扣非归母净利润171.35亿元，同比下降6.04%。2020Q3，板块营收和归母净利润分别同比增长-1.04%和11.54%，业绩增速较Q1和Q2有所回升。◼4）生物制品：Q3业绩增速环比显著回升，疫苗业绩加速增长。2020年前三季度，SW生物制品板块实现营业总收入906.37亿元，同比下降2.58%；实现归属于母公司股东的净利润158.98亿元，同比增长25.2%。2020Q3，板块营收和归母净利润分别同比增长11.98%和52.16%，增速较Q1和Q2显著回升。细分板块中，疫苗Q3业绩加速增长，血制品收入恢复正增长。疫苗类公司智飞生物、沃森生物业绩保持高增。血制品龙头和生物药龙头Q3业绩呈现环比回升之势。专题研究行业研究证券研究报告医药生物行业2020年三季报业绩综述2请务必阅读末页声明。◼5）医药商业：Q3业绩增速环比明显回升。2020年前三季度，SW医药商业板块实现营业总收入5429.7亿元，同比增长2.2%；实现归属于母公司股东的净利润143.1亿元，同比增长9.95%。2020Q3，板块营收和归母净利润分别同比增长10.8%和24.88%，增速环比明显回升。细分板块中，Q3医药零售业绩保持快增，医药批发业绩增速环比明显回升。◼6）医疗器械：Q3业绩保持高增。2020年前三季度，SW医疗器械板块实现营业总收入1401.04亿元，同比增长51.93%；实现归属于母公司股东的净利润396.28亿元，同比增长133.45%。2020Q3，板块营收和归母净利润分别同比增长71.47%和198.7%，Q3业绩保持高增。细分板块中，Q3体外诊断、医用耗材、医疗设备业绩保持高增。◼7）医疗服务：Q3业绩增速环比持续回升。2020年前三季度，SW医疗服务板块实现营业总收入536.18亿元，同比增长8.4%；归母净利润69.34亿元，同比增长24.8%。2020Q3，板块营收和归母净利润分别同比增长25.6%和31.3%，增速环比持续回升。细分板块中，2020Q3，CRO收入端保持快增，净利润端增速同比有所下降；连锁医疗业绩恢复正增长，美年健康实现扭亏为盈。◼投资策略：维持对行业的推荐评级。建议从中长期的角度优选优质赛道的优质龙头：（1）研发实力强的创新药龙头。（2）政策免疫、景气度有望持续向好的医疗服务龙头。（3）创新能力强的器械龙头。（4）渠道扩张能力强的医药零售龙头。（5）研发能力强、重磅产品有望放量、在研重磅产品有望上市的疫苗龙头。医药生物行业2020年三季报业绩综述3请务必阅读末页声明。目录1.医药生物行业整体业绩.........................................................................................................................................62.子行业业绩情况.....................................................................................................................................................72.1化学原料药..................................................................................................................................................72.1.1Q3业绩增速有所回落....................................................................................................................72.1.2盈利能力有所提升.........................................................................................................................82.2化学制剂......................................................................................................................................................92.2.1Q3业绩增速环比有所回升............................................................................................................92.2.2盈利能力：前三季度毛利率有所下降.......................................................................................102.3中药.............................................................................................................................................................102.3.1Q3业绩增速环比有所回升..........................................................................................................102.3.2Q3盈利能力环比有所回升..........................................................................................................112.4生物制品....................................................................................................................................................122.4.1Q3业绩增速环比显著回升..........................................................................................................122.4.2盈利能力持续回升.......................................................................................................................132.5医药商业...................................................................................................................................................142.5.1Q3业绩增速环比明显回升..........................................................................................................142.5.2盈利能力有所提升.......................................................................................................................152.6医疗器械...................................................................................................................................................162.6.1Q3业绩保持高增..........................................................................................................................162.6.2盈利能力持续上升.......................................................................................................................162.7医疗服务...................................................................................................................................................172.7.1Q3业绩增速环比持续回升..........................................................................................................172.7.2Q3盈利能力有所回升..................................................................................................................183.投资策略................................................................................................................................................................194.风险提示................................................................................................................................................................20医药生物行业2020年三季报业绩综述4请务必阅读末页声明。插图目录图1：SW医药生物行业单季业绩（亿元）................................................6图2：SW医药生物行业单季业绩同比增速（%）...........................................6图3：医药生物行业细分板块单季营收同比增速（%）......................................6图4：医药生物行业细分板块单季归母净利润同比增速（%）................................6图5：化学原料药板块单季业绩（亿元）.................................................7图6：化学原料药板块单季业绩同比增速（%）............................................7图7：化学原料药板块毛利率净利率（%）................................................8图8：化学原料药板块期间费用率（%）..................................................8图9：化学制剂板块单季业绩（亿元）...................................................9图10：化学制剂板块单季业绩同比增速（%）.............................................9图11：化学制剂板块毛利率净利率（%）................................................10图12：化学制剂板块期间费用率（%）..................................................10图13：中药板块单季业绩（亿元）....................................................11图14：中药板块单季业绩同比增速（%）................................................11图15：中药板块毛利率净利率（%）....................................................11图16：中药板块期间费用率（%）.....................................................11图17：生物制品板块单季业绩（亿元）.................................................12图18：生物制品板块单季业绩同比增速（%）............................................12图19：生物制品板块毛利率净利率（%）................................................13图20：生物制品板块期间费用率（%）..................................................13图21：医药商业板块单季业绩（亿元）.................................................14图22：医药商业板块单季业绩同比增速（%）............................................14图23：医药商业板块毛利率净利率（%）................................................15图24：医药商业板块期间费用率（%）..................................................15图25：医疗器械板块单季业绩（亿元）.................................................16图26：医疗器械板块单季业绩同比增速（%）............................................16图27：医疗器械板块毛利率净利率（%）................................................17图28：医疗器械板块期间费用率（%）..................................................17图29：医疗服务板块单季业绩（亿元）.................................................17图30：医疗服务板块单季业绩同比增速（%）............................................17图31：医疗服务板块毛利率净利率（%）................................................18图32：医疗服务板块期间费用率（%）..................................................18表格目录表1：2020前三季度化学原料药板块重点上市公司业绩简况.................................7表2：2020前三季度化学原料药板块重点上市公司盈利能力.................................8表3：2020年前三季度化学制剂板块净利润规模前十大公司业绩简况.........................9表4：2020年前三季度化学制剂板块净利润规模前十大公司盈利能力........................10表5：2020前三季度中药板块净利润规模前十大上市公司业绩简况..........................11表6：2020前三季度中药板块净利润规模前十大上市公司盈利能力..........................12表7：2020前三季度生物制品板块重点公司业绩简况.....................................13医药生物行业2020年三季报业绩综述5请务必阅读末页声明。表8：2020前三季度生物制品板块重点公司盈利能力.....................................14表9：2020前三季度医药商业板块重点上市公司业绩简况..................................14表10：2020前三季度医药商业板块重点上市公司盈利能力.................................15表11：2020前三季度医疗器械板块净利润规模前十大上市公司业绩简况.....................16表12：2020前三季度医疗器械板块净利润规模前十大上市公司盈利能力.....................17表13：2020前三季度医疗服务板块重点上市公司业绩简况.................................18表14：2020前三季度医疗服务板块重点上市公司盈利能力.................................19表15：重点公司盈利预测及投资评级（2020/11/13）.....................................19医药生物行业2020年三季报业绩综述6请务必阅读末页声明。1.医药生物行业整体业绩2020Q3业绩增速有所回升。2020年前三季度，SW医药生物行业（剔除B股，共353家样本公司）实现营业总收入13519.43亿元，同比增长2.44%；实现归属于母公司股东的净利润1315.2亿元，同比增长24.84%；实现扣非归母净利润1141.7亿元，同比增长28.59%。2020Q3，SW医药生物行业分别实现营收和归母净利润为5558.78亿元和573.85亿元，分别同比增长9.4%和39.15%，Q3业绩增速较Q1和Q2有所回升。疫情受损板块Q3业绩有所回升。细分板块中，前三季度业绩表现最好的是医疗器械，主要是受益疫情。化学原料药、生物制品、医药商业和医疗服务业绩均实现正增长，化学制剂和中药业绩仍有所下滑。从单季业绩来看，Q3化学原料药业绩增速环比有所回落，医疗器械保持快增，化学制剂、中药、生物制品、医药商业和医疗服务业绩增速环比均有所回升。图1：SW医药生物行业单季业绩（亿元）图2：SW医药生物行业单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图3：医药生物行业细分板块单季营收同比增速（%）图4：医药生物行业细分板块单季归母净利润同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述7请务必阅读末页声明。2.子行业业绩情况2.1化学原料药2.1.1Q3业绩增速有所回落2020Q3增速有所回落。2020年前三季度，SW化学原料药板块实现营业总收入771.85亿元，同比增长5.16%，增速同比下降3个百分点；实现归属于母公司股东的净利润125.7亿元，同比增长14.76%，增速同比下降7.7个百分点。2020Q3，SW化学原料药板块营收和归母净利润分别同比增长2.71%和-15.67%，Q3收入增速环比回落主要受产品价格环比回落影响所致，净利润同比有所下滑主要受投资收益减少影响所致。表1：2020前三季度化学原料药板块重点上市公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）002001.SZ新和成74.7329.3728.9572.5213.8432.47002019.SZ亿帆医药41.429.119.1222.794.18-24.86600521.SH华海药业48.718.4121.4164.2315.2048.10002626.SZ金达威25.697.9411.8550.4129.3489.45002399.SZ海普瑞35.427.0912.855.56-12.562.13000739.SZ普洛药业58.116.307.3045.99-2.5233.08600216.SH浙江医药54.306.212.0772.309.65143.95603707.SH健友股份21.586.1318.0836.6917.0628.44300702.SZ天宇股份20.045.7826.6230.0711.173.48002099.SZ海翔药业19.523.62-17.84-47.550.14-50.42600267.SH海正药业81.543.43-1.90-72.717.16-91.53300497.SZ富祥药业11.092.9414.6835.89-21.90-27.03300765.SZ新诺威10.332.577.5820.5612.731.79000756.SZ新华制药46.392.464.692.033.42-19.88图5：化学原料药板块单季业绩（亿元）图6：化学原料药板块单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述8请务必阅读末页声明。资料来源：东莞证券研究所，wind2.1.2盈利能力有所提升前三季度盈利能力有所提升。2020年前三季度，化学原料药板毛利率同比提高3.38个百分点至40.25%；期间费用率同比下降0.58个百分点至17.57%，主要得益于销售费用率的下降；净利率同比提高1.38个百分点至16.66%，主要得益于毛利率提升和费用率下降。表2：2020前三季度化学原料药板块重点上市公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）002001.SZ新和成58.4539.4313.4811.619.72-0.53002019.SZ亿帆医药49.2921.3523.134.892.36-0.17600521.SH华海药业63.8018.2141.344.464.68-4.41002626.SZ金达威55.7431.5219.618.278.38-0.57002399.SZ海普瑞39.2919.9424.893.88-0.980.14000739.SZ普洛药业28.2210.8417.05-3.802.87-5.02600216.SH浙江医药42.0910.8829.101.824.41-2.97603707.SH健友股份59.3928.2327.678.583.694.62300702.SZ天宇股份54.8528.8422.220.470.762.16002099.SZ海翔药业46.3118.5423.32-4.43-10.507.95600267.SH海正药业44.267.3237.78-0.88-10.36-6.10300497.SZ富祥药业43.8426.8113.351.384.09-1.26300765.SZ新诺威57.2724.9029.615.152.662.90000756.SZ新华制药29.015.7621.31-2.46-0.04-2.52603229.SH奥翔药业56.2421.9331.683.61-2.794.89图7：化学原料药板块毛利率净利率（%）图8：化学原料药板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述9请务必阅读末页声明。资料来源：东莞证券研究所，wind2.2化学制剂2.2.1Q3业绩增速环比有所回升2020Q3业绩增速环比有所回升。2020年前三季度，SW化学制剂板块实现营业总收入2242.98亿元，同比下降8.46%；实现归属于母公司股东的净利润213.87亿元，同比下降0.15%；实现扣非归母净利润171.35亿元，同比下降6.04%。2020Q3，板块营收和归母净利润分别同比增长-2.03%和36.1%，业绩增速较Q1和Q2有所回升。板块内多数公司Q3业绩增速环比有所回升。前三季度板块内仍有近15%的公司亏损。从Q3单季业绩来看，板块内约有77%的公司收入增速环比有所回升，约有56%的公司净利润增速环比有所回升。前十大公司中，恒瑞医药、丽珠集团、健康元、现代制药、康弘药业Q3业绩增速有所回升。表3：2020年前三季度化学制剂板块净利润规模前十大公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）600276.SH恒瑞医药194.1342.5914.5714.0217.1320.74000963.SZ华东医药255.0123.91-7.708.06-5.757.04000623.SZ吉林敖东16.1615.04-31.4829.66-30.9268.13000513.SZ丽珠集团79.2614.228.6436.7120.1438.52600380.SH健康元101.039.278.7419.1120.678.11600062.SH华润双鹤63.748.73-13.95-4.93-12.3813.90002437.SZ誉衡药业22.156.58-44.32111.94-34.86-114.50600420.SH现代制药93.646.313.769.7813.8350.40600079.SH人福医药148.466.13-7.81-17.83-7.02-46.11002773.SZ康弘药业23.485.79-2.564.857.1515.32图9：化学制剂板块单季业绩（亿元）图10：化学制剂板块单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述10请务必阅读末页声明。资料来源：东莞证券研究所，wind2.2.2盈利能力：前三季度毛利率有所下降前三季度毛利率有所下滑，净利率微幅提升。2020年前三季度，SW化学制剂板块毛利率同比下降0.9个百分点至54.04%；期间费用率同比下降0.85个百分点至36.91%，主要受益于销售费用率下降。净利率同比提高0.79个百分点至10.83%，主要得益于费用率下降和投资净收益提升。表4：2020年前三季度化学制剂板块净利润规模前十大公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）600276.SH恒瑞医药87.7221.8661.570.54-0.18-0.26000963.SZ华东医药34.709.6524.102.361.311.77000623.SZ吉林敖东61.6592.5357.93-9.0843.57-1.22000513.SZ丽珠集团66.1423.0441.281.456.94-3.79600380.SH健康元64.5621.5841.26-0.884.92-4.02600062.SH华润双鹤64.1913.8447.01-0.211.28-1.38002437.SZ誉衡药业72.9730.0672.50-0.2322.179.43600420.SH现代制药46.398.4635.75-4.91-0.27-4.92600079.SH人福医药42.527.0332.533.230.261.59002773.SZ康弘药业90.2224.6663.20-2.071.74-3.65资料来源：东莞证券研究所，wind2.3中药2.3.1Q3业绩增速环比有所回升Q3业绩增速环比有所回升。2020年前三季度，SW中药板块实现营业总收入2242.98亿元，同比下降8.46%；实现归属于母公司股东的净利润213.87亿元，同比下降0.15%；实现扣非归母净利润171.35亿元，同比下降6.04%。2020Q3，板块营收和归母净利润分别同比增长-1.04%和11.54%，业绩增速较Q1和Q2有所回升。图11：化学制剂板块毛利率净利率（%）图12：化学制剂板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述11请务必阅读末页声明。板块内多数公司Q3业绩增速环比有所回升。前三季度受益疫情的以岭药业、红日药业等公司业绩保持快增；多数疫情受损的公司Q3业绩增速环比有所回升。净利润规模前十大公司中，白云山、华润三九、片仔癀、济川药业、同仁堂业绩增速环比有所回升。表5：2020前三季度中药板块净利润规模前十大上市公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）000538.SZ云南白药239.3142.5310.5620.088.8938.95600332.SH白云山468.8526.59-6.35-15.84-1.8346.22000999.SZ华润三九92.4115.64-9.29-20.5712.86103.74603858.SH步长制药112.4413.969.783.469.67-10.18600436.SH片仔癀50.7013.2916.7819.8326.0128.05600535.SH天士力113.9111.00-19.17-2.84-40.8077.25002603.SZ以岭药业64.4710.1648.3176.7443.84151.25600566.SH济川药业43.149.60-19.90-26.50-7.87-19.63600085.SH同仁堂90.537.15-9.09-15.898.8323.83300026.SZ红日药业47.095.9930.7216.0546.5653.85资料来源：东莞证券研究所，wind2.3.2Q3盈利能力环比有所回升前三季度盈利能力有所下降，Q3盈利能力环比有所回升。2020年前三季度，SW中药板块毛利率同比下降2.37个百分点至43.7%；期间费用率同比下降1.58个百分点至30.19%，主要受益于销售费用率和财务费用率的下降；净利率同比下降1.07个百分点至9.72%。Q3板块毛利率、净利率分别环比回升0.75个百分点和0.26个百分点。图13：中药板块单季业绩（亿元）图14：中药板块单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图15：中药板块毛利率净利率（%）图16：中药板块期间费用率（%）医药生物行业2020年三季报业绩综述12请务必阅读末页声明。表6：2020前三季度中药板块净利润规模前十大上市公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）000538.SZ云南白药29.6117.7513.35-0.091.41-2.13600332.SH白云山19.446.0411.97-2.28-0.71-2.36000999.SZ华润三九63.0617.0842.29-3.48-2.39-8.58603858.SH步长制药76.9112.4161.26-6.43-0.88-5.71600436.SH片仔癀47.3526.6816.112.590.861.99600535.SH天士力35.419.7522.374.031.611.29002603.SZ以岭药业62.2115.7442.71-4.282.57-7.02600566.SH济川药业81.9422.2455.63-2.51-2.00-0.27600085.SH同仁堂47.9112.4731.51-1.08-1.470.65300026.SZ红日药业58.2112.6242.86-11.55-1.94-9.01资料来源：东莞证券研究所，wind2.4生物制品2.4.1Q3业绩增速环比显著回升Q3业绩增速环比显著回升，疫苗业绩加速增长。2020年前三季度，SW生物制品板块实现营业总收入906.37亿元，同比下降2.58%；实现归属于母公司股东的净利润158.98亿元，同比增长25.2%。2020Q3，板块营收和归母净利润分别同比增长11.98%和52.16%，增速较Q1和Q2显著回升。细分板块中，疫苗Q3业绩加速增长，血制品收入恢复正增长。疫苗类公司智飞生物、沃森生物业绩保持高增。血制品龙头和生物药龙头Q3业绩呈现环比回升之势。资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图17：生物制品板块单季业绩（亿元）图18：生物制品板块单季业绩同比增速（%）医药生物行业2020年三季报业绩综述13请务必阅读末页声明。表7：2020前三季度生物制品板块重点公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）600196.SH复星医药221.0324.794.1220.1214.4539.57300122.SZ智飞生物110.5024.7944.1440.5954.3758.13000661.SZ长春高新63.9922.6017.5582.1920.9684.91002252.SZ上海莱士20.3810.966.3880.8017.80106.71002007.SZ华兰生物30.739.6416.460.0436.45-0.96600867.SH通化东宝21.867.566.249.8214.1837.41603087.SH甘李药业21.926.8618.263.7410.04-3.86600161.SH天坛生物26.364.974.626.4212.7123.05688363.SH华熙生物15.964.3823.965.1235.6512.78300142.SZ沃森生物15.674.3596.46261.79234.49955.45300601.SZ康泰生物14.204.331.870.58-6.170.49300357.SZ我武生物4.912.29-1.79-7.082.645.14资料来源：东莞证券研究所，wind2.4.2盈利能力持续回升盈利能力持续回升。2020年前三季度，SW生物制品板块毛利率同比提升0.61个百分点至56.52%；期间费用率同比下降1.68个百分点至31.28%，得益于销售费用率下降；净利率同比提升2.7个百分点至18.72%。板块Q3毛利率净利率同比环比均有所回升。资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图19：生物制品板块毛利率净利率（%）图20：生物制品板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述14请务必阅读末页声明。表8：2020前三季度生物制品板块重点公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）600196.SH复星医药55.8712.4448.18-3.920.87-4.35300122.SZ智飞生物40.0222.4311.69-1.92-0.57-1.21000661.SZ长春高新86.3938.7039.820.456.01-4.72002252.SZ上海莱士63.0653.6019.58-1.4622.03-5.98002007.SZ华兰生物67.9134.7628.424.50-3.757.61600867.SH通化东宝78.9034.4639.174.151.113.04603087.SH甘李药业91.3031.3152.10-0.92-4.381.73600161.SH天坛生物48.2727.8015.11-0.860.62-0.64688363.SH华熙生物80.8827.3851.601.90-4.8912.74300142.SZ沃森生物86.2934.5655.546.6214.45-4.35300601.SZ康泰生物92.9130.5158.001.02-0.391.11300357.SZ我武生物95.4445.4942.53-1.07-3.083.77资料来源：东莞证券研究所，wind2.5医药商业2.5.1Q3业绩增速环比明显回升Q3业绩增速环比明显回升。2020年前三季度，SW医药商业板块实现营业总收入5429.7亿元，同比增长2.2%；实现归属于母公司股东的净利润143.1亿元，同比增长9.95%。2020Q3，板块营收和归母净利润分别同比增长10.8%和24.88%，增速环比明显回升。细分板块中，Q3医药零售业绩保持快增，医药批发业绩增速环比明显回升。表9：2020前三季度医药商业板块重点上市公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）603233.SH大参林104.928.6730.4955.9027.3955.21603368.SH柳药股份117.546.085.8211.136.9111.62002727.SZ一心堂92.396.0420.5924.8023.3927.87图21：医药商业板块单季业绩（亿元）图22：医药商业板块单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述15请务必阅读末页声明。603939.SH益丰药房94.375.9027.7241.1634.3261.59603883.SH老百姓101.204.8720.9123.6021.0421.88601607.SH上海医药1,403.2336.02-0.215.9710.654.18600998.SH九州通803.2021.419.46110.2316.11220.44600056.SH中国医药302.6712.3816.3027.8025.0164.35600511.SH国药股份291.1110.05-11.00-6.21-0.9221.54000028.SZ国药一致428.819.988.773.9813.6514.14资料来源：东莞证券研究所，wind2.5.2盈利能力有所提升前三季度盈利能力有所提升。2020年前三季度，SW医药商业板块毛利率同比提高0.11个百分点至13.49%；期间费用率同比下降0.15个百分点至9.28%；净利率同比提高0.24个百分点至3.19%。表10：2020前三季度医药商业板块重点上市公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）603233.SH大参林38.588.3927.19-1.241.53-3.00002727.SZ一心堂36.236.5427.97-2.550.22-3.06603939.SH益丰药房38.497.0428.99-1.140.71-1.89603368.SH柳药股份12.585.535.530.210.080.09603883.SH老百姓32.505.9225.23-1.390.35-1.63601607.SH上海医药14.373.1110.580.380.23-0.14600998.SH九州通9.113.236.210.891.83-0.17600056.SH中国医药16.094.689.39-3.010.10-3.70000028.SZ国药一致11.512.858.230.69-0.050.56600511.SH国药股份7.823.713.42-0.45-0.10-0.11图23：医药商业板块毛利率净利率（%）图24：医药商业板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述16请务必阅读末页声明。资料来源：东莞证券研究所，wind2.6医疗器械2.6.1Q3业绩保持高增Q3业绩保持高增。2020年前三季度，SW医疗器械板块实现营业总收入1401.04亿元，同比增长51.93%；实现归属于母公司股东的净利润396.28亿元，同比增长133.45%。2020Q3，板块营收和归母净利润分别同比增长71.47%和198.7%，Q3业绩保持高增。细分板块中，Q3体外诊断、医用耗材、医疗设备业绩保持高增。表11：2020前三季度医疗器械板块净利润规模前十大上市公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）300760.SZ迈瑞医疗160.6453.6329.7646.0931.7546.65300677.SZ英科医疗89.4543.73486.443,376.72730.874,363.39300676.SZ华大基因67.5227.05225.82901.68238.611,361.54603301.SH振德医疗81.1720.98531.522,105.57721.273,068.48688289.SH圣湘生物36.0520.131,381.4710,702.391,864.847,480.61300003.SZ乐普医疗63.8719.738.6322.389.7382.28002382.SZ蓝帆医疗46.5518.8879.14403.16159.93800.69002030.SZ达安基因35.6015.37363.611,817.41465.773,759.55002223.SZ鱼跃医疗48.4815.1036.33111.8435.34117.70002950.SZ奥美医疗30.899.5980.46340.0935.07133.21资料来源：东莞证券研究所，wind2.6.2盈利能力持续上升毛利率净利率均持续上升。2020年前三季度，SW医疗器械板块毛利率同比提高5.98个百分点至58.17%；期间费用率同比下降5.26个百分点至19.64%，主要得益于销售费用率和管理费用率下降；净利率同比提高10.23个百分点至29.21%，主要受益于毛利率提升和费用率下降。Q3毛利率净利率均持续提升。图25：医疗器械板块单季业绩（亿元）图26：医疗器械板块单季业绩同比增速（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述17请务必阅读末页声明。表12：2020前三季度医疗器械板块净利润规模前十大上市公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）300760.SZ迈瑞医疗66.8433.3929.831.623.72-1.92300677.SZ英科医疗68.5248.889.2644.1040.63-4.79300676.SZ华大基因64.6140.4616.758.9927.46-21.38603301.SH振德医疗46.4729.6910.3914.5921.60-13.71688289.SH圣湘生物82.1955.8316.0517.7548.17-40.98300003.SZ乐普医疗69.7431.4839.02-2.903.99-4.46002382.SZ蓝帆医疗62.8240.6618.4516.8425.42-10.23002030.SZ达安基因69.0342.1918.9017.5433.30-19.20002223.SZ鱼跃医疗56.0331.0822.2014.1010.853.65002950.SZ奥美医疗43.7531.1010.9110.3418.44-8.16资料来源：东莞证券研究所，wind2.7医疗服务2.7.1Q3业绩增速环比持续回升Q3业绩增速环比持续回升。2020年前三季度，SW医疗服务板块实现营业总收入536.18亿元，同比增长8.4%；归母净利润69.34亿元，同比增长24.8%。2020Q3，板块营收和归母净利润分别同比增长25.6%和31.3%，增速环比持续回升。细分板块中，2020Q3，CRO收入端保持快增，净利润端增速同比有所下降；连锁医疗业绩恢复正增长，美年健康实现扭亏为盈。图27：医疗器械板块毛利率净利率（%）图28：医疗器械板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图29：医疗服务板块单季业绩（亿元）图30：医疗服务板块单季业绩同比增速（%）医药生物行业2020年三季报业绩综述18请务必阅读末页声明。表13：2020前三季度医疗服务板块重点上市公司业绩简况证券代码证券简称2020Q1-Q3营收（亿元）2020Q1-Q3归母净利润（亿元）2020Q1-Q3营收同比（%）2020Q1-Q3归母净利润同比（%）2020Q3营收同比（%）2020Q3归母净利润同比（%）603259.SH药明康德118.1523.6827.3434.1735.44-8.07300347.SZ泰格医药23.0013.1813.27149.5722.3181.37300759.SZ康龙化成35.867.8936.53140.2840.6985.62603127.SH昭衍新药6.321.1881.2353.1958.6515.85688202.SH美迪西4.330.7538.2560.0950.2142.06300015.SZ爱尔眼科85.6515.4610.7825.6047.5562.34600763.SH通策医疗14.523.962.22-0.9824.4930.68002044.SZ美年健康44.19-5.17-29.61-232.15-1.22-29.15资料来源：东莞证券研究所，wind2.7.2Q3盈利能力有所回升Q3盈利能力有所回升。2020年前三季度，SW医疗器服务板块毛利率同比下降1.53个百分点至37%；期间费用率同比下降0.16个百分点至21.51%，主要受益于销售费用率和管理费用率下降；净利率受益于公允价值变动净收益大幅增长同比提高1.4个百分点至13.71%。板块Q3毛利率净利率均有所回升。资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind图31：医疗服务板块毛利率净利率（%）图32：医疗服务板块期间费用率（%）资料来源：东莞证券研究所，wind资料来源：东莞证券研究所，wind医药生物行业2020年三季报业绩综述19请务必阅读末页声明。表14：2020前三季度医疗服务板块重点上市公司盈利能力证券代码证券简称2020Q1-Q3毛利率（%）2020Q1-Q3净利率（%）2020Q1-Q3期间费用率（%）2020Q1-Q3毛利率同比（%）2020Q1-Q3净利率同比（%）2020Q1-Q3期间费用率同比（%）603259.SH药明康德37.5820.2021.30-1.930.613.46300347.SZ泰格医药48.4860.9925.741.5832.576.49300759.SZ康龙化成37.7421.3716.894.159.28-0.86603127.SH昭衍新药49.7818.5631.72-1.78-3.243.89688202.SH美迪西37.4217.9817.561.332.68-1.73300015.SZ爱尔眼科47.6519.6222.13-0.772.74-2.65600763.SH通策医疗45.9930.4812.72-1.94-0.93-0.22002044.SZ美年健康28.91-12.2041.67-12.56-19.375.86资料来源：东莞证券研究所，wind3.投资策略维持对行业的推荐评级。随着国内疫情的控制，受损疫情板块的景气度持续回升。新冠疫苗研发持续稳步推进，上市希望在即，短期可关注疫情受损板块龙头的估值修复。从中长期角度仍要关注优质赛道的优质龙头：（1）研发实力强的创新药龙头。（2）政策免疫、景气度有望持续向好的医疗服务龙头。（3）创新能力强的器械龙头。（4）渠道扩张能力强的医药零售龙头。（5）研发能力强、重磅产品有望放量、在研重磅产品有望上市的疫苗龙头。表15：重点公司盈利预测及投资评级（2020/11/13）股票代码股票名称股价(元)EPS（元）PE评级评级变动2019A2020E2021E2019A2020E2021E600276恒瑞医药85.501.001.241.5885.569.054.1推荐维持000963华东医药29.191.611.711.9918.117.114.7谨慎推荐维持000513丽珠集团45.121.381.812.1032.724.921.5谨慎推荐维持600196复星医药57.331.301.401.6744.141.034.3谨慎推荐维持000661长春高新354.044.387.179.2180.849.438.4推荐维持300357我武生物58.860.570.610.83103.396.570.9推荐维持603259药明康德117.700.761.261.48154.993.479.5推荐维持300347泰格医药124.610.961.951.97129.863.963.3推荐维持300759康龙化成114.390.691.351.57165.884.772.9推荐维持603127昭衍新药103.000.781.171.62132.188.063.6推荐维持002821凯莱英266.052.283.304.26116.780.662.5推荐维持300122智飞生物131.941.482.092.9289.163.145.2推荐维持002007华兰生物44.630.700.911.0663.849.042.1推荐维持000538云南白药97.413.283.544.0029.727.524.4谨慎推荐维持600436片仔癀222.702.282.753.4297.781.065.1谨慎推荐维持300760迈瑞医疗343.853.855.166.2689.366.654.9推荐维持603658安图生物156.061.721.942.7790.780.456.3推荐维持医药生物行业2020年三季报业绩综述20请务必阅读末页声明。300529健帆生物68.750.711.011.3496.868.151.3推荐维持300463迈克生物45.250.941.251.5548.136.229.2推荐维持300595欧普康视71.270.510.640.87139.7111.481.9推荐维持600529山东药玻45.560.770.971.2259.247.037.3推荐维持300015爱尔眼科68.850.330.420.57208.6163.9120.8推荐维持600763通策医疗242.801.441.441.84168.6168.6132.0推荐维持603233大参林99.201.071.521.9592.765.350.9推荐维持002727一心堂37.351.021.251.4836.629.925.2推荐维持603939益丰药房108.361.021.381.81106.278.559.9推荐维持603883老百姓70.801.241.551.9257.145.736.9推荐维持603882金域医学86.200.882.782.3298.031.037.2推荐维持资料来源：Wind，东莞证券研究所4.风险提示（1）全球新冠疫情持续扩散。（2）研发推进低于预期。（3）行业政策风险。（4）产品安全质量风险等。（5）原料价格波动风险。（6）药品降价风险等。医药生物行业2020年三季报业绩综述21请务必阅读末页声明。东莞证券投资评级体系：公司投资评级推荐预计未来6个月内，股价表现强于市场指数15%以上谨慎推荐预计未来6个月内，股价表现强于市场指数5%-15%之间中性预计未来6个月内，股价表现介于市场指数±5%之间回避预计未来6个月内，股价表现弱于市场指数5%以上行业投资评级推荐预计未来6个月内，行业指数表现强于市场指数10%以上谨慎推荐预计未来6个月内，行业指数表现强于市场指数5%-10%之间中性预计未来6个月内，行业指数表现介于市场指数±5%之间回避预计未来6个月内，行业指数表现弱于市场指数5%以上风险等级评级低风险宏观经济及政策、财经资讯、国债等方面的研究报告中低风险债券、货币市场基金、债券基金等方面的研究报告中风险可转债、股票、股票型基金等方面的研究报告中高风险科创板股票、新三板股票、权证、退市整理期股票、港股通股票等方面的研究报告高风险期货、期权等衍生品方面的研究报告本评级体系“市场指数”参照标的为沪深300指数。分析师承诺：本人具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，以勤勉的职业态度，独立、客观地在所知情的范围内出具本报告。本报告清晰准确地反映了本人的研究观点，不受本公司相关业务部门、证券发行人、上市公司、基金管理公司、资产管理公司等利益相关者的干涉和影响。本人保证与本报告所指的证券或投资标的无任何利害关系，没有利用发布本报告为自身及其利益相关者谋取不当利益，或者在发布证券研究报告前泄露证券研究报告的内容和观点。声明：东莞证券为全国性综合类证券公司，具备证券投资咨询业务资格。本报告仅供东莞证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因接收人收到本报告而视其为客户。本报告所载资料及观点均为合规合法来源且被本公司认为可靠，但本公司对这些信息的准确性及完整性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断，可随时更改。本报告所指的证券或投资标的的价格、价值及投资收入可跌可升。本公司可发出其它与本报告所载资料不一致及有不同结论的报告，亦可因使用不同假设和标准、采用不同观点和分析方法而与本公司其他业务部门或单位所给出的意见不同或者相反。在任何情况下，本报告所载的资料、工具、意见及推测只提供给客户作参考之用，并不构成对任何人的投资建议。投资者需自主作出投资决策并自行承担投资风险，据此报告做出的任何投资决策与本公司和作者无关。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任，任何形式的分享证券投资收益或者分担证券投资损失的书面或口头承诺均为无效。本公司及其所属关联机构在法律许可的情况下可能会持有本报告中提及公司所发行的证券头寸并进行交易，还可能为这些公司提供或争取提供投资银行、经纪、资产管理等服务。本报告版权归东莞证券股份有限公司及相关内容提供方所有，未经本公司事先书面许可，任何人不得以任何形式翻版、复制、刊登。如引用、刊发，需注明本报告的机构来源、作者和发布日期，并提示使用本报告的风险，不得对本报告进行有悖原意的引用、删节和修改。未经授权刊载或者转发本证券研究报告的，应当承担相应的法律责任。东莞证券研究所广东省东莞市可园南路1号金源中心24楼邮政编码：523000电话：（0769）22119430传真:（0769）22119430网址：www.dgzq.com.cn","data":[{"id":"1","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医药生物行业（剔除B股，共353家样本公司）实现营业总收入13519.43亿元","content_offset":["246","297"],"indicators":[{"indicator_name":"营业收入","indicator_value":["13519.43亿元","287","297"],"indicator_element":{"时间":["2020年前三季度","246","255"],"行业":["SW医药生物","256","262"],"公司":["剔除B股，共353家样本公司","265","279"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长2.44%","content_offset":["298","307"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["2.44%","302","307"],"indicator_element":{"时间":["2020年前三季度","246","255"],"行业":["SW医药生物","256","262"],"公司":["剔除B股，共353家样本公司","265","279"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，SW医药生物行业分别实现营收和归母净利润为5558.78亿元和573.85亿元","content_offset":["371","417"],"indicators":[{"indicator_name":"营业收入","indicator_value":["5558.78亿元","399","408"],"indicator_element":{"时间":["2020Q3","371","377"],"行业":["SW医药生物","378","384"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，SW医药生物行业分别实现营收和归母净利润为5558.78亿元和573.85亿元","content_offset":["371","417"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["573.85亿元","409","417"],"indicator_element":{"时间":["2020Q3","371","377"],"行业":["SW医药生物","378","384"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"分别同比增长9.4%和39.15%","content_offset":["418","435"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["9.4%","424","428"],"indicator_element":{"时间":["2020Q3","371","377"],"行业":["SW医药生物","378","384"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"分别同比增长9.4%和39.15%","content_offset":["418","435"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["39.15%","429","435"],"indicator_element":{"时间":["2020Q3","371","377"],"行业":["SW医药生物","378","384"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW化学原料药板块实现营业总收入771.85亿元","content_offset":["630","664"],"indicators":[{"indicator_name":"营业收入","indicator_value":["771.85亿元","656","664"],"indicator_element":{"时间":["2020年前三季度","630","639"],"行业":["SW化学原料药","640","647"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长5.16%","content_offset":["665","674"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["5.16%","669","674"],"indicator_element":{"时间":["2020年前三季度","630","639"],"行业":["SW化学原料药","640","647"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"增速同比下降3个百分点","content_offset":["675","686"],"indicators":[{"indicator_name":"营业收入增长率同比","indicator_value":["下降3个百分点","679","686"],"indicator_element":{"时间":["2020年前三季度","630","639"],"行业":["SW化学原料药","640","647"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，SW化学原料药板块营收和归母净利润分别同比增长2.71%和-15.67%","content_offset":["734","777"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["2.71%","764","769"],"indicator_element":{"时间":["2020Q3","734","740"],"行业":["SW化学原料药","741","748"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，SW化学原料药板块营收和归母净利润分别同比增长2.71%和-15.67%","content_offset":["734","777"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["-15.67%","770","777"],"indicator_element":{"时间":["2020Q3","734","740"],"行业":["SW化学原料药","741","748"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW化学制剂板块实现营业总收入2242.98亿元","content_offset":["852","886"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2242.98亿元","877","886"],"indicator_element":{"时间":["2020年前三季度","852","861"],"行业":["SW化学制剂","862","868"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比下降8.46%","content_offset":["887","896"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下降8.46%","889","896"],"indicator_element":{"时间":["2020年前三季度","852","861"],"行业":["SW化学制剂","862","868"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长2.03%和36.1%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["2.03%","22","27"],"indicator_element":{"时间":["2020Q3","-1","5"],"行业":["SW化学制剂","862","868"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长2.03%和36.1%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["36.1%","28","33"],"indicator_element":{"时间":["2020Q3","-1","5"],"行业":["SW化学制剂","862","868"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW中药板块实现营业总收入2242.98亿元","content_offset":["1026","1058"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2242.98亿元","1049","1058"],"indicator_element":{"时间":["2020年前三季度","1026","1035"],"行业":["SW中药","1036","1040"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比下降8.46%","content_offset":["887","896"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下降8.46%","889","896"],"indicator_element":{"时间":["2020年前三季度","852","861"],"行业":["SW中药","1036","1040"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长-1.04%和11.54%","content_offset":["1130","1166"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-1.04%","1153","1159"],"indicator_element":{"时间":["2020Q3","1130","1136"],"行业":["SW中药","1036","1040"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长-1.04%和11.54%","content_offset":["1130","1166"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["11.54%","1160","1166"],"indicator_element":{"时间":["2020Q3","1130","1136"],"行业":["SW中药","1036","1040"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW生物制品板块实现营业总收入906.37亿元","content_offset":["1212","1245"],"indicators":[{"indicator_name":"营业收入","indicator_value":["906.37亿元","1237","1245"],"indicator_element":{"时间":["2020年前三季度","1212","1221"],"行业":["SW生物制品","1222","1228"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比下降2.58%","content_offset":["1246","1255"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下降2.58%","1248","1255"],"indicator_element":{"时间":["2020年前三季度","1212","1221"],"行业":["SW生物制品","1222","1228"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长11.98%和52.16%","content_offset":["1289","1325"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["11.98%","1312","1318"],"indicator_element":{"时间":["2020Q3","1289","1295"],"行业":["SW生物制品","1222","1228"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长11.98%和52.16%","content_offset":["1289","1325"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["52.16%","1319","1325"],"indicator_element":{"时间":["2020Q3","1289","1295"],"行业":["SW生物制品","1222","1228"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医药商业板块实现营业总收入5429.7亿元","content_offset":["1476","1509"],"indicators":[{"indicator_name":"营业收入","indicator_value":["5429.7亿元","1501","1509"],"indicator_element":{"时间":["2020年前三季度","1476","1485"],"行业":["SW医药商业","1486","1492"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长2.2%","content_offset":["1510","1518"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["2.2%","1514","1518"],"indicator_element":{"时间":["2020年前三季度","1476","1485"],"行业":["SW医药商业","1486","1492"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长10.8%和24.88%","content_offset":["1551","1586"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["10.8%","1574","1579"],"indicator_element":{"时间":["2020Q3","1551","1557"],"行业":["SW医药商业","1486","1492"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长10.8%和24.88%","content_offset":["1551","1586"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["24.88%","1580","1586"],"indicator_element":{"时间":["2020Q3","1551","1557"],"行业":["SW医药商业","1486","1492"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医疗器械板块实现营业总收入1401.04亿元","content_offset":["1647","1681"],"indicators":[{"indicator_name":"营业收入","indicator_value":["1401.04亿元","1672","1681"],"indicator_element":{"时间":["2020年前三季度","1647","1656"],"行业":["SW医疗器械","1657","1663"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长51.93%","content_offset":["1682","1692"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["51.93%","1686","1692"],"indicator_element":{"时间":["2020年前三季度","1647","1656"],"行业":["SW医疗器械","1657","1663"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长71.47%和198.7%","content_offset":["1728","1764"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["71.47%","1751","1757"],"indicator_element":{"时间":["2020Q3","1728","1734"],"行业":["SW医疗器械","1657","1663"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长71.47%和198.7%","content_offset":["1728","1764"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["198.7%","1758","1764"],"indicator_element":{"时间":["2020Q3","1728","1734"],"行业":["SW医疗器械","1657","1663"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医疗服务板块实现营业总收入536.18亿元","content_offset":["1824","1857"],"indicators":[{"indicator_name":"营业收入","indicator_value":["536.18亿元","1849","1857"],"indicator_element":{"时间":["2020年前三季度","1824","1833"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长8.4%","content_offset":["1858","1866"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["8.4%","1862","1866"],"indicator_element":{"时间":["2020年前三季度","1824","1833"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"归母净利润69.34亿元","content_offset":["1867","1879"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["69.34亿元","1872","1879"],"indicator_element":{"时间":["2020年前三季度","1824","1833"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"同比增长24.8%","content_offset":["1880","1889"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["24.8%","1884","1889"],"indicator_element":{"时间":["2020年前三季度","1824","1833"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长25.6%和31.3%","content_offset":["1890","1924"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["25.6%","1913","1918"],"indicator_element":{"时间":["2020Q3","1890","1896"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020Q3，板块营收和归母净利润分别同比增长25.6%和31.3%","content_offset":["1890","1924"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["31.3%","1919","1924"],"indicator_element":{"时间":["2020Q3","1890","1896"],"行业":["SW医疗服务","1834","1840"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，化学原料药板毛利率同比提高3.38个百分点至40.25%","content_offset":["10596","10634"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["40.25%","10628","10634"],"indicator_element":{"时间":["2020年前三季度","10596","10605"],"行业":["化学原料药","10606","10611"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比提高1.38个百分点至16.66%","content_offset":["10674","10696"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["16.66%","10690","10696"],"indicator_element":{"时间":["2020年前三季度","10596","10605"],"行业":["化学原料药","10606","10611"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW化学制剂板块毛利率同比下降0.9个百分点至54.04%","content_offset":["12638","12677"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["54.04%","12671","12677"],"indicator_element":{"时间":["2020年前三季度","12638","12647"],"行业":["SW化学制剂","12648","12654"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比提高0.79个百分点至10.83%","content_offset":["12716","12738"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["10.83%","12732","12738"],"indicator_element":{"时间":["2020年前三季度","12638","12647"],"行业":["SW化学制剂","12648","12654"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW中药板块毛利率同比下降2.37个百分点至43.7%","content_offset":["14363","14400"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["43.7%","14395","14400"],"indicator_element":{"时间":["2020年前三季度","14363","14372"],"行业":["SW中药","14373","14377"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比下降1.07个百分点至9.72%","content_offset":["14446","14467"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["9.72%","14462","14467"],"indicator_element":{"时间":["2020年前三季度","14363","14372"],"行业":["SW中药","14373","14377"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"Q3板块毛利率、净利率分别环比回升0.75个百分点和0.26个百分点","content_offset":["14468","14502"],"indicators":[{"indicator_name":"毛利率环比","indicator_value":["0.75个百分点","14485","14493"],"indicator_element":{"时间":["Q3","14468","14470"],"行业":["SW中药","14373","14377"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"Q3板块毛利率、净利率分别环比回升0.75个百分点和0.26个百分点","content_offset":["14468","14502"],"indicators":[{"indicator_name":"净利率环比","indicator_value":["0.26个百分点","14494","14502"],"indicator_element":{"时间":["Q3","14468","14470"],"行业":["SW中药","14373","14377"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW生物制品板块毛利率同比提升0.61个百分点至56.52%","content_offset":["16224","16264"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["56.52%","16258","16264"],"indicator_element":{"时间":["2020年前三季度","16224","16233"],"行业":["SW生物制品","16234","16240"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比提升2.7个百分点至18.72%","content_offset":["16301","16322"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["18.72%","16316","16322"],"indicator_element":{"时间":["2020年前三季度","16224","16233"],"行业":["SW生物制品","16234","16240"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医药商业板块毛利率同比提高0.11个百分点至13.49%","content_offset":["18024","18064"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["13.49%","18058","18064"],"indicator_element":{"时间":["2020年前三季度","18024","18033"],"行业":["SW医药商业","18034","18040"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比提高0.24个百分点至3.19%","content_offset":["18089","18110"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["3.19%","18105","18110"],"indicator_element":{"时间":["2020年前三季度","18024","18033"],"行业":["SW医药商业","18034","18040"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医疗器械板块毛利率同比提高5.98个百分点至58.17%","content_offset":["19604","19644"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["58.17%","19638","19644"],"indicator_element":{"时间":["2020年前三季度","19604","19613"],"行业":["SW医疗器械","19614","19620"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率同比提高10.23个百分点至29.21%","content_offset":["19689","19712"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["29.21%","19706","19712"],"indicator_element":{"时间":["2020年前三季度","19604","19613"],"行业":["SW医疗器械","19614","19620"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"2020年前三季度，SW医疗器服务板块毛利率同比下降1.53个百分点至37%","content_offset":["21301","21339"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["37%","21336","21339"],"indicator_element":{"时间":["2020年前三季度","21301","21310"],"行业":["SW医疗服务","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"医药生物行业2020年三季报业绩综述：Q3业绩增速环比有所回.pdf","content":"净利率受益于公允价值变动净收益大幅增长同比提高1.4个百分点至13.71%","content_offset":["21384","21421"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["13.71%","21415","21421"],"indicator_element":{"时间":["2020年前三季度","21301","21310"],"行业":["SW医疗服务","-1","-1"]},"indicator_supplement":{"属性":""}}]}]}